Tango Therapeutics
Cambridge
About Tango Therapeutics
Tango Therapeutics operator of a biotechnology company created to discover novel drug targets and deliver the next generation of targeted therapies to people with cancer. The company's research leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer that are focused on three core areas, including counteracting tumor suppressor gene loss, reversing the ability of cancer cells to evade the immune system and identifying novel combinations, enabling patients to get therapies that are more effective than single-agent therapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $628.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nasdaq:TNGX
- Website: tangotx.com
- Phone: (857) 320-4900
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/tango-therapeutics-59531 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.